GENELUX CORP.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | GNLX |
| ISIN: |
GENELUX CORP. news, videos and press releases
For more news please use our advanced search feature.
GENELUX CORP. - More news...
GENELUX CORP. - More news...
- 03/28/2025 - 20:10 Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- 03/25/2025 - 12:31 Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
- 03/25/2025 - 12:30 Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
- 03/25/2025 - 12:30 Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
- 02/03/2025 - 11:45 Genelux Corporation Announces New Chief Financial Officer
- 12/13/2024 - 12:01 Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
- 11/14/2024 - 21:05 Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
- 11/06/2024 - 21:01 Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
- 10/22/2024 - 20:01 Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
- 10/09/2024 - 20:15 Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
- 09/03/2024 - 20:01 Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
- 08/14/2024 - 20:05 Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
- 07/30/2024 - 11:00 Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
- 05/24/2024 - 12:00 Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
- 05/23/2024 - 20:01 Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
- 05/09/2024 - 20:25 Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
- 04/01/2024 - 11:00 Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- 11/27/2023 - 12:00 Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
- 11/14/2023 - 22:50 Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
- 09/14/2023 - 11:00 Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 09/07/2023 - 20:01 Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
- 08/28/2023 - 11:00 Genelux Corporation Announces New Chief Financial Officer
- 08/14/2023 - 11:00 Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
- 08/02/2023 - 20:00 Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
- 07/20/2023 - 20:45 Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
- 07/10/2023 - 11:00 Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
- 06/29/2023 - 11:00 Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
- 06/22/2023 - 11:00 Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
- 06/12/2023 - 11:00 Genelux Corporation Announces $18 Million Private Placement
- 05/25/2023 - 20:01 Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
